Chandigarh College of Technology
Landran
Mohali
Announces
International Symposium on Formulating Medicines -Confronting Cancer
Thursday, 29th April, 2010
At
Department of Biotechnology,
Landran, Mohali
Landran, Mohali
An endeavor of
Chandigarh Group of Colleges
Landran, Mohali
Chandigarh Group of Colleges
Chandigarh Group of Colleges is one of the pioneer institute, located on the outskirts of the city beautiful Chandigarh, adding to the prestige and distinction of the famous city. The group offers educational programmes at the under graduate and post graduate level in Biotechnology, Pharmacy, Engineering, Business Management, Airlines & Tourism, Computer Applications and Education.
Department of Biotechnology, CCT
The Department of Biotechnology, Chandigarh College of Technology was established in the year 2006. Since then this department has been at the forefront of providing education in a highly professional set up, adhering to global standards and setting benchmarks for the industry. The mission of this college is to provide value based quality education, produce professionally competent students for career in biotechnology and raise quality trained manpower to meet the requirements of national and international industry. Department of Biotechnology offers a two years Master’s degree and a three years Bachelor’s degree in Biotechnology. This symposium is a part of the series of activities undertaken by this department in its effort to showcase the state of the art research and development in the area of biotechnology. The Symposium will bring the academician and researcher together at a common platform to promote future interdisciplinary activity and research in these areas.
Overview
Cancer is a class of diseases in which a group of cells exhibit uncontrolled growth, invasion and sometimes metastasis. According to a report by WHO, cancer is the world’s second biggest killer after cardiovascular disease, but one of the most preventable noncommunicable chronic diseases. The symposium is being organized in order to create awareness on basic concept and recent advances in cancer therapies among the students and teachers.
Nanobiotechnology beyond boundaries, RNA silencing through Nanocarriers, Delivery to cellular RNA Interference: Promises of cancer gene therapy: Prof. Jagat R. Kanwar, Laboratory of Immunology and Molecular Medical Research, Deakin University, Australia.
This lecture focuses on cancer gene therapy to silence the survivin gene with nanotechnological delivery systems. siRNA was loaded to survivin and oncogenic antisense micro RNA 27a on alginate gel encapsulated, chitosan ceramic nanocores nanocarriers (ACNC-NPs) and transferred to human breast cancers and colon cancer cell lines by endocytosis.miR-27a loaded ACNC-NPs exhibit oncogenic activity. Supression of miR-27a inhibits breast cancer cell growth and invasion.
Epigenetics and Cancer Therapy: Prof. Kulbhushan Tikoo, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education & Research (NIPER), Mohali.
The concept of epigenetics in the development of human cancer has been growing rapidly during the past decade. The underlying idea of epigenetics in cancer therapy involves changing the gene expression profile rather than killing the cancerous cells. Histone deactylase (HDAC) inhibitors are emerging as potent anti-cancer drugs that target the family of enzymes catalyzing the removal of the acetyl modification on lysine residues of proteins, including the core nucleosomal histones H2, H2B, H3 and H4.
Molecular Pathogenesis of colon carcinogenesis; exploring the P13 Kinase/Akt/GSk3 beta pathway and COX -2 inhibitors : Prof. S.N. Sanyal, Department of Biophysics, Panjab University, Chandigarh.
In addition to having anti-inflammatory properties, non-steroidal anti-inflammatory drugs (NSAIDs) inhibit neoplastic cell proliferation by inducing apoptosis. Recently, a major role for phosphatidyl inositol-3kinase (PI3-kinase) and Wnt pathway activation in human tumors has been established. The present study explored the role of PI3-kinase and Wnt molecular pathways in NSAIDs’ chemopreventive effect in colon cancer.
Targetted therapy in Hepatocellular carcinoma: Prof. Yogesh Chawla,Head of the department, Department of Hepatology, Post Graduate Institute of Medial Education & Research (PGIMER), Chandigarh
Hepatocellular cancer (HCC) is the third leading cause of cancer death.The effectiveness of targeted therapy with monoclonal antibodies or small-molecule kinase inhibitors has now been demonstrated for the treatment of different tumors. Recently, the multitargeted kinase inhibitor, sorafenib, was found to prolong survival significantly for patients with advanced HCC.
FORMULATING MEDICINES-CONFRONTING CANCER
Symposium Details
Timings
Symposium Schedule
10:30- 11:00 Hrs Welcome Note
11:00-11:30 Hrs Prof. Peter Beech: Introduction about Deakin University
11:30-12:15 Hrs Prof. K. Tikoo: Epigenetics and cancer therapy
12:15-01:00 Hrs Prof. Jagat R. Kanwar: NanoBiotechnology beyond Boundaries, RNA Silencing through Nanocarriers: Promises of Cancer Gene Therapy
01:00-01:45 Hrs Lunch Break
01:45-02:30 Hrs Prof. S.N. Sanyal: Molecular Pathogenesis of colon carcinogenesis; exploring the P13 Kinase/Akt/GSk3 beta pathway and COX -2 inhibitors
02:30-03:10 Hrs Prof. Yogesh Chawla: Targeted therapy in hepatocellular carcinoma
03:10-03:20 Hrs Valedictory function
Organizing Team
Symposium Convener:
Prof. Upendra K. Jain
Principal
Chandigarh College of Technology
Landran, Mohali-140307
Office: 0172-3984209
Mobile: 97819-25277
Email: upendrachl@gmail.com
Organizing Secretary:
Dr. Rakesh Bijarnia
Asst. Professor
Department of Biotechnology
Landran, Mohali-140307
Symposium Coordinators:
Mrs. Palki Sahib Kaur, Sr. Lecturer, Biotechnology, 98767-27271Mr. Love Kumar, Sr. Lecturer, Biotechnology, 97819-99191Ms. Nidhi Gupta, Lecturer, Biotechnology, 98725-82773Ms. Irshita Kaushik, Lecturer, Biotechnology, 92161-02027Mr. Vikas Menon, Sr. Lecturer, Biotechnology, 94631-11445
There is no registration fee and confirm your arrival at drbijarnia@gmail.com
Request from Rakesh Bijarnia, PhD, Organizing Secretary
.png)
0 Comments